Complete Cancer Care includes a Lymphedema Prevention Program
Prevent Lymphedema with a 30-second, Noninvasive Test
Cancer-related lymphedema is one of the most serious sequelae associated with cancer treatment. Implementing a Lymphedema Prevention Program not only improves patients’ health, it can increase the value of your cancer center.
1 in 3 of at-risk cancer patients will develop lymphedema1,2
The Benefits of Establishing a Lymphedema Prevention Program
Attract & Retain More Patients
Provide specialized care and more effective treatment options by establishing a Lymphedema Prevention Plan (LPP). A comprehensive LPP allows cancer centers to attract more patients and retain them throughout adjuvant therapy.
Meet Accreditation Standards
Several cancer treatment guidelines recommend that patients be assessed for lymphedema using a pretreatment baseline test and regular post-surgical testing with a goal of early detection. Cancer centers offering a prevention program also meet quality metrics set by the NAPBC, APTA, eviCore® and COC.
Effectively Prevent Lymphedema
Utilize bioimpedance spectroscopy (BIS) technology to effectively monitor and measure a patient’s fluid status. A single SOZO® reading allows clinicians across multiple specialties to provide individualized, proactive care.
Obtain Reliable, Precise Fluid Readings in Seconds
SOZO®, the world’s most advanced, noninvasive bioimpedance spectroscopy (BIS) device, incorporates L-Dex® technology, The FDA-cleared, CE-marked and ARTG-listed digital health platform aids in the early detection of secondary lymphedema and can be used to monitor and maintain overall health.
Guidelines for Implementing a Lymphedema Prevention Program
Test. Trigger. Treat.TM
Test
Test Upon Diagnosis & Periodically after Cancer Surgery
It is important for cancer patients to establish a baseline L-Dex score once diagnosed with breast cancer, melanoma, or pelvic area cancers. After cancer surgery, patients should be tested every 3 months for the first 3 years, every 6 months for years 4 and 5, and annually thereafter2.
Trigger
Evaluate Elevated L-Dex Readings above the Baseline
Clinical evidence shows that patients with an L-Dex score of 6.5 or more from the baseline after surgery should seek immediate intervention3.
Treat
Apply Treatment to Reduce Lymphedema Progression
Compression garments worn at home for 4 weeks, 12 hours per day, has shown to reduce the progression of lymphedema by 95% in breast cancer patients3.
Accurately Measure Fluid Status at Point of Care
Securely Share Data Across Your Healthcare System with MySOZO
The SOZO® platform stores user accounts, patient records, measurement data, other calculated measures and trends in a proprietary and secure MySOZO cloud. This allows medical staff to quickly and easily share information with anyone with proper credentials.
Establish a Lymphedema Prevention Program for Your Cancer Center
Offering a lymphedema prevention plan will become essential to complete cancer care as the awareness of lymphedema prevention continues to grow among the medical and patient communities. Download our guide to learn more about the advantages of adding a lymphedema prevention program to your cancer care center.
Together, We Can End Cancer-Related Lymphedema
Contact us to learn about SOZO® with L-Dex® and the benefits of supporting a Lymphedema Prevention Program.
References
- Shaitelman SF, et al. Recent Progress in the Treatment and Prevention of Cancer-Related Lymphedema. CA Cancer J Clin. 2015;00:00–00.
- Brown JC, et al. The Prevalence of Lymphedema Symptoms among Long-Term Cancer Survivors with or at-risk for Lower Limb Lymphedema. Am J Phys Med Rehabil. 2013 March ; 92(3): 223–231. doi:10.1097/PHM.0b013e31826edd97.
- Shah C, et al. Bioimpedance Spectroscopy for Breast Cancer Related Lymphedema Assessment: Clinical Practice Guidelines. The Breast Journal 2016;DOI: 10.1111/tbj.12647.
- Ridner SH, et al. A Randomized Trial Evaluating Bioimpedance Spectroscopy Versus Tape Measurement for the Prevention of Lymphedema Following Treatment for Breast Cancer: Interim Analysis. Ann Surg Oncol 2019; https://doi.org/10.1245/s10434-019-07344-5.
General or Sales Inquiries
enquiries@impedimed.com
1 +61-7-3860-3700
U.S. Headquarters
5900 Pasteur Ct.
Ste. 125
Carlsbad, CA 92008 USA
+1-877-BIS-0111 or
+1-877-247-0111 (Toll Free)
Phone: +1-760-585-2100
Fax: +1-760-804-9245
info@impedimed.com
European Office
Registered Office
Unit 1
50 Parker Court
Pinkenba, QLD 4008 Australia
Phone: + 61-7-3860-3700
Fax: + 61-7-3260-1225
Free call: 1-800-638-477
enquiries@impedimed.com